Being less toxic, gefitinib and erlotinib have been reported to be superior to conventional cytotoxic chemotherapy in terms of RR and PFS time in lung adenocarcinoma patients with EGFR mutations such as L858R (EGFR addiction). Here, EGFR is linked to lung adenocarcinoma.